Mark Rowen

Mark leads Alliance Management at Denali and is responsible for the industry and academic collaborations that are central to Denali's corporate strategy. Working closely with Business Development and project teams, Alliance Management establishes and fosters these strategic relationships to build value for Denali and their partners. Together with their partners, they deepen their scientific expertise, extend their capabilities and accelerate their ability to discover, develop and commercialize medicines for neurodegenerative diseases. Mark brings over 20 years of experience leading the sourcing, assessing, negotiating and managing of biopharma partnerships. Prior to joining Denali in 2019, Mark spent 13 years at Genentech and Roche, most recently as Genentech's Head of Business Development for Technology Platforms focused on in-licensing drug discovery technologies across therapeutic modalities and disease areas. Mark has a B.Sc. in Chemistry from the University of Guelph in Canada.